Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model
Audiology Research · 28.02.2026 · 16 (2) · 36
DOI: 10.3390/audiolres16020036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Audiology Research, online erschienen am 28.02.2026. Verfasst von Sung Kyun Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Kresge Hearing Research Institute, Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Department of Defense (DoD).
Abstract (Originalsprache)
Background/Objectives: Blast-induced hearing loss (BIHL) is a major concern, particularly for military personnel, and is linked to impaired auditory neuron survival and synaptic plasticity. This study investigates the potential of the TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) to reduce the severity of BIHL and promote recovery in a mouse model.
Methods
Eight-week-old male C57BL/6J mice were used. A custom-built, compressed air-driven system utilizing a modified paintball apparatus was employed to deliver controlled unilateral double blasts (~22 psi exposure pressure) to the left ear. The blasts were administered 30 min apart. Immediately following the second blast, mice received either 7,8-DHF (10 mg/kg) or vehicle (10% DMSO) via intraperitoneal injection. Auditory brainstem responses (ABRs) were measured in both ears at baseline (pre-blast) and at several post-exposure time points.
Results
The consecutive blast exposure induced a significant elevation in ABR thresholds, indicative of hearing loss, in both the ipsilateral (exposed) and contralateral (unexposed) ears of vehicle-treated mice. Notably, mice treated with 7,8-DHF demonstrated a marked improvement in hearing recovery compared to the vehicle group. Significant reductions in ABR thresholds were observed in the ipsilateral ear at 4 weeks post-blast (p < 0.0001) and in the contralateral ear as early as 1-week post-blast (p = 0.0236). However, the recovery was partial, with ABR thresholds plateauing after 4 weeks.
Conclusions
A controlled blast model demonstrates that systemic administration of the TrkB agonist 7,8-DHF exerts a protective effect, partially restoring auditory function after blast injury. This supports the therapeutic potential of targeting the BDNF-TrkB signaling pathway for managing BIHL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kresge Hearing Research Institute, Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Han-Gyu Bae, Jun Hee Kim
Förderung
- the Department of Defense (DoD)
Zitieren
APA
Kim, S. K., Bae, H. G., & Kim, J. H. (2026). Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model. Audiology Research, 16(2), 36. https://doi.org/10.3390/audiolres16020036
Vancouver
Kim SK, Bae HG, Kim JH. Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model. Audiology Research. 2026;16(2):36. doi:10.3390/audiolres16020036
BibTeX
@article{Kim2026,
author = {Kim, Sung Kyun and Bae, Han-Gyu and Kim, Jun Hee},
title = {Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model},
journal = {Audiology Research},
year = {2026},
volume = {16},
number = {2},
pages = {36},
doi = {10.3390/audiolres16020036}
}
EUVIMED